Staphylococcus aureus is a common bacterial species in humans, but can become nasty if it gets into the wrong part of the body. have been shown to reduce the risk of infection without the dangers of antibiotics.
Staphylococcus aureus Found in the nose, intestines, and skin of many people, it is mostly harmless. But if it gets into a wound, bloodstream, lungs, or other unintended place, it can cause serious infections. is increasing. Staphylococcus aureus (MRSA) or “golden staph” is becoming a common nosocomial infection.
Reducing the harmless population in the body has been suggested as a way to reduce the risk of serious infections, but using antibiotics to do so is not ideal.
For a new study, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) investigated using probiotics instead. molecule Bacillus subtilis interfered with the sensing system of Staphylococcus aureuswhich stops the growth of the latter. Bacillus subtilis Already used as a human probiotic.
In a new clinical trial, 115 participants naturally hosted colonies. Staphylococcus aureus given either Bacillus subtilis or placebo daily for 30 days. Researchers then assessed levels of bacteria in the nose and gut and compared them to levels at the start of the study. And sure enough, those who took probiotics Staphylococcus aureus 65.4% reduction in intestinal populations, and nasal. On the other hand, no changes were detected in the control group.
“The probiotics we use do not ‘kill’ Staphylococcus aureus, but it specifically and strongly reduces the ability to colonize,” said lead investigator of the trial, Dr. Michael Otto. “We think we can target the ‘bad’ stuff. Staphylococcus aureus while leaving the composition of the microflora intact. “
The team says the technology could be an effective preventive treatment for people at high risk of infection. Staphylococcus aureussince Bacillus subtilis is already widely used as a probiotic and is much safer than antibiotics for long-term use.
The researchers plan to follow it up with another trial that will test more people over a longer period of time.
The study was published in a journal lancet microbe.
Source: NIAID
